Sylvester Comprehensive Cancer Center

  • 20201130 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:

    IRB: 20201130

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: SCCC

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Plantation
    Sylvester

    Title:

    Single-arm, open-label phase 2 study of loncastuximab tesirine in combination with rituximab in patients with advanced stage follicular lymphoma

    Eligibility Criteria - NCT04998669 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210957 - Alderuccio Juan

  • Investigator:
    Juan Alderuccio
    RCname Email

    Coordinator:

    IRB: 20210957

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: SWOG

    Enrolling Sites:

    Sylvester

    Title:

    A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC and BCL2 and/or BCL6 Rearrangements

    Eligibility Criteria - NCT04799275 *This information has been extracted from " www.clinicaltrials.gov"

  • LOXO-BTK-18001 - Alencar, Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    Coordinator:

    IRB: 20190647

    SDG: Lymphoma
    Disease Site(s):

    Leukemia, Other,Lymphoid Leukemia,Non-Hodgkin Lymphoma

    Sponsor: LOXO ONCOLOGY

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1/2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Non-Hodgkin Lymphoma (NHL)

    Eligibility Criteria - NCT03740529 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191273 - Alencar Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    Coordinator:

    IRB: 20191273

    SDG: Lymphoma
    Disease Site(s):

    Leukemia, Other,Leukemia, not otherwise specified,Lymphoid Leukemia

    Sponsor: DANA-FARBER CANCER INSTITUTE

    Enrolling Sites:

    Sylvester
    UMH

    Title:

    A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome

    Eligibility Criteria - NCT03534323 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210481 - Alencar Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20210481

    SDG: Lymphoma
    Disease Site(s):

    Other Hematopoietic

    Sponsor: LOXO ONCOLOGY

    Enrolling Sites:

    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester
    UMH

    Title:

    A Phase 1 Study of Oral LOXO-338, a Selective BCL-2 Inhibitor, in Patients with Advanced Hematologic Malignancies

    Eligibility Criteria - NCT05024045 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210550 - Alencar Alvaro

  • Investigator:
    Alvaro Alencar
    RCname Email

    Coordinator:

    IRB: 20210550

    SDG: Lymphoma
    Disease Site(s):

    Lymphoid Leukemia

    Sponsor: Alliance for Clinical Trials in Oncology

    Enrolling Sites:

    Deerfield
    Sylvester

    Title:

    Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab (Nivo-MR2) Induction Followed by Lenalidomide and Nivolumab Maintenance in Primary CNS Lymphoma

    Eligibility Criteria - NCT04609046 *This information has been extracted from " www.clinicaltrials.gov"

  • KTE-C19-102 - Beitinjaneh, Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:

    IRB: 20151004

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Kite

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-X19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2)

    Eligibility Criteria - NCT02601313 *This information has been extracted from " www.clinicaltrials.gov"

  • EBV-CTL-302 - Beitinjaneh, Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:

    IRB: 20161025

    SDG: Lymphoma
    Disease Site(s):

    Other Hematopoietic

    Sponsor: Atara

    Enrolling Sites:

    Sylvester

    Title:

    Multicenter, Open Label, Phase 3 Trial of Allogeneic Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs) for Solid Organ Transplant (SOT) Patients with EBV-Associated Post Transplant Lymphoproliferative Disease (EBV-PTLD) after Failure of Rituximab or Rituximab and Chemotherapy

    Eligibility Criteria - NCT03394365 *This information has been extracted from " www.clinicaltrials.gov"

  • EA4151 - Beitinjaneh, Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:

    IRB: 20180272

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: ECOG

    Enrolling Sites:

    Sylvester

    Title:

    EA4151: A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma In Minimal Residual Disease-Negative First Complete Remission

    Eligibility Criteria - NCT03267433 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200606 - Beitinjaneh Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:

    IRB: 20200606

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma,Leukemia, Other,Non-Hodgkin Lymphoma

    Sponsor: CRISPR Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1, Open-Label, Multicenter, Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Anti-CD70 Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Adult Subjects With Relapsed or Refractory T or B Cell Malignancies

    Eligibility Criteria - NCT04502446 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220279 - Beitinjaneh Amer

  • Investigator:
    Amer Beitinjaneh
    RCname Email

    Coordinator:

    IRB: 20220279

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma

    Sponsor: Tessa Therapeutics

    Enrolling Sites:

    Sylvester

    Title:

    Phase 1b Study Evaluating the Safety and Efficacy of Autologous CD30.CAR-T in Combination with Programmed Cell Death Protein-1 Checkpoint Inhibitor (Nivolumab) in Relapsed or Refractory Classical Hodgkin Lymphoma Patients after Failure of FrontlineTherapy (ACTION)

  • TAPUR - Calfa, Carmen

  • Investigator:
    Carmen Calfa
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20170529

    SDG: Breast Cancer
    Disease Site(s):

    Breast,Colon,Kaposis sarcoma,Kidney,Larynx,Liver,Lymphoid Leukemia,Multiple,Multiple Myeloma,Non-Hodgkin Lymphoma,Pancreas,Prostate,Soft Tissue

    Sponsor: ASCO

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    The Targeted Agent and Profiling Utilization Registry (TAPUR) Study

    Eligibility Criteria - NCT02693535 *This information has been extracted from " www.clinicaltrials.gov"

  • MATCH - Huang, Marilyn

  • Investigator:
    Marilyn Huang
    RCname Email

    Coordinator:
    RCemailImg Carolina Troche
    RCphone +1 (305) 2431481

    IRB: 20150671

    SDG: Gynecologic Cancer
    Disease Site(s):

    Cervix Uteri,Colon,Corpus Uteri,Kaposis sarcoma,Kidney,Larynx,Liver,Multiple Myeloma,Non-Hodgkin Lymphoma,Other Female Genital,Ovary,Pancreas,Prostate,Soft Tissue

    Sponsor: ECOG

    Enrolling Sites:

    Coral Springs
    Deerfield
    Gables
    Hollywood
    Kendall
    Plantation
    Sylvester

    Title:

    Molecular Analysis for Therapy Choice (MATCH)

    Eligibility Criteria - NCT02465060 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210450 - Jimenez Antonio

  • Investigator:
    Antonio Jimenez
    RCname Email

    Coordinator:
    RCemailImg Robby Friedman
    RCphone +1 (561) 7060311

    IRB: 20210450

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma,Leukemia, Other,Lymphoid Leukemia,Mycosis Fungoides,Myeloid and Monocytic Leukemia,Non-Hodgkin Lymphoma

    Sponsor: NATIONAL MARROW DONOR PROGRAM

    Enrolling Sites:

    Sylvester

    Title:

    A Multi-Center, Phase II Trial of HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide for Patients with Hematologic Malignancies

    Eligibility Criteria - NCT04904588 *This information has been extracted from " www.clinicaltrials.gov"

  • Alexander - Lekakis, Lazaros

  • Investigator:
    Lazaros Lekakis
    RCname Email

    Coordinator:

    IRB: 20190669

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: AUTOLUS

    Enrolling Sites:

    Sylvester

    Title:

    A Single Arm, Open-label, Multi-centre, Phase I/II Study Evaluating the Safety and Clinical Activity of AUTO3, a CAR T Cell Treatment Targeting CD19 and CD22 With Anti PD1 Antibody in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma

    Eligibility Criteria - NCT03287817 *This information has been extracted from " www.clinicaltrials.gov"

  • 20200541 - Lekakis Lazaros

  • Investigator:
    Lazaros Lekakis
    RCname Email

    Coordinator:

    IRB: 20200541

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: ALLOGENE

    Enrolling Sites:

    Sylvester

    Title:

    A RANDOMIZED, OPEN-LABEL, PHASE 1/2 STUDY EVALUATING THE SAFETY, EFFICACY, AND CELLULAR KINETICS/PHARMACODYNAMICS OF ALLO-501A, AN ANTI-CD19 ALLOGENEIC CAR T CELL THERAPY, AND ALLO-647, AN ANTI-CD52 MONOCLONAL ANTIBODY, IN SUBJECTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (LBCL)

    Eligibility Criteria - NCT03939026 *This information has been extracted from " www.clinicaltrials.gov"

  • ACE-LY-003 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20180457

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Acerta

    Enrolling Sites:

    Sylvester

    Title:

    ACE-LY-003: An Open-label, Phase 1b/2 Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B Cell Non-Hodgkin Lymphoma

    Eligibility Criteria - NCT02180711 *This information has been extracted from " www.clinicaltrials.gov"

  • 20180458 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20180458

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: NCI

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    ILyAD (Indolent Lymphoma And Vitamin D): A Phase III Double Blind, Prospective Randomized Trial to Evaluate the Supplemental Effect of Vitamin D (Cholecalciferol) on Progression-free Survival in Patients With Low Tumor-burden Indolent Non-Hodgkin Lymphoma Treated With Rituximab Therapy

    Eligibility Criteria - NCT03078855 *This information has been extracted from " www.clinicaltrials.gov"

  • GO40516 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20180637

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Sylvester

    Title:

    GO40516:An Open-Label, Randomized, Multicenter, Phase Ib/II Trial Evaluating The Safety, Tolerability, Pharmacokinetics, and Efficacy Of Mosunetuzumab (BTCT4465A) In Combination With Polatuzumab Vedotin In Patients With B-Cell Non-Hodgkin Lymphoma Lymphoma

    Eligibility Criteria - NCT03671018 *This information has been extracted from " www.clinicaltrials.gov"

  • GO40515 - Lossos, Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20180638

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Hoffmann - La Roche

    Enrolling Sites:

    Sylvester

    Title:

    GO40515: A Phase Ib/II, Open-Label, Multicenter, Randomized, Controlled Study Investigating The Safety, Tolerability, Pharmacokinetics, And Efficacy OfMosunetuzumab (BTCT4465) In Combination With CHOP or CHP-PolatuzumabVedotin In Patients With B-Cell Non-Hodgkin Lymphoma

    Eligibility Criteria - NCT03677141 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191008 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:

    IRB: 20191008

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma,Non-Hodgkin Lymphoma

    Sponsor: MEI PHARMA

    Enrolling Sites:

    Sylvester

    Title:

    A Three-Arm Study of ME-401 Monotherapy in Subjects with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) or Follicular Lymphoma (FL), of ME-401 in Combination with Rituximab in Subjects with Relapsed/Refractory CLL/SLL or B-cell Non-Hodgkin?s Lymphoma (NHL), and of ME-401 in Combination with Zanubrutinib in Subjects with Relapsed/Refractory CLL/SLL or B-cell NHL

    Eligibility Criteria - NCT02914938 *This information has been extracted from " www.clinicaltrials.gov"

  • 20211204 - Lossos Izidore

  • Investigator:
    Izidore Lossos
    RCname Email

    Coordinator:
    RCemailImg Sara Haddadi
    RCphone +1 (305) 243-3557

    IRB: 20211204

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    A phase 2, open-label, study evaluating safety and efficacy of theloncastuximab in relapsed/refractory marginal zone lymphoma

    Eligibility Criteria - NCT05296070 *This information has been extracted from " www.clinicaltrials.gov"

  • CPI-006-001 - Merchan, Jaime

  • Investigator:
    Jaime Merchan
    RCname Email

    Coordinator:
    RCemailImg Rakhi Modak
    RCphone +1 (305) 2437387

    IRB: 20180279

    SDG: Prostate, Bladder, and Kidney Cancers
    Disease Site(s):

    Bladder,Bones and Joints,Cervix Uteri,Colon,Corpus Uteri,Kidney,Lip, Oral Cavity and Pharynx,Lung,Lymphoid Leukemia,Non-Hodgkin Lymphoma,Pancreas,Prostate,Rectum,Soft Tissue

    Sponsor: CP

    Enrolling Sites:

    Sylvester

    Title:

    CPI-006-001: A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD 73 Antibody, CPI-006, As A Single Agent, In Combination WIith CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

    Eligibility Criteria - NCT03454451 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190755 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    Coordinator:

    IRB: 20190755

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma

    Sponsor: Memorial Sloan-Kettering Cancer Center

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma

    Eligibility Criteria - NCT03618550 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190758 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    Coordinator:

    IRB: 20190758

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma

    Sponsor: Memorial Sloan-Kettering Cancer Center

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

    Eligibility Criteria - NCT03179917 *This information has been extracted from " www.clinicaltrials.gov"

  • 20191083 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    Coordinator:

    IRB: 20191083

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma

    Sponsor: SWOG

    Enrolling Sites:

    Gables
    Hollywood
    Sylvester

    Title:

    A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) With Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma - S1826

    Eligibility Criteria - NCT03907488 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220026 - Moskowitz Craig

  • Investigator:
    Craig Moskowitz
    RCname Email

    Coordinator:

    IRB: 20220026

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma

    Sponsor: ASTRA ZENECA

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I/II Open-label, Multi-center Study to Assess Safety,Tolerability, Pharmacokinetics and Preliminary Efficacy ofAZD7789, an anti-PD-1 and anti-TIM-3 Bispecific Antibody, inPatients with Relapsed or Refractory Classical HodgkinLymphoma

    Eligibility Criteria - NCT05216835 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210661 - Pereira Denise

  • Investigator:
    Denise Pereira
    RCname Email

    Coordinator:

    IRB: 20210661

    SDG: Lymphoma
    Disease Site(s):

    Multiple Myeloma,Other Hematopoietic

    Sponsor: CELGENE

    Enrolling Sites:

    Sylvester

    Title:

    EXPANDED ACCESS PROTOCOL (EAP) FOR SUBJECTS RECEIVING IDECABTAGENE VICLEUCEL THAT IS NONCONFORMING FOR COMMERCIAL RELEASE

    Eligibility Criteria - NCT04771078 *This information has been extracted from " www.clinicaltrials.gov"

  • 20150567 - Ramos Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20150567

    SDG: Lymphoma
    Disease Site(s):

    Leukemia, Other,Non-Hodgkin Lymphoma

    Sponsor: SCCC

    Enrolling Sites:

    JMH
    Sylvester

    Title:

    A Phase II Trial of Belinostat as Consolidation Therapy with Zidovudine for Adult T-Cell Leukemia-Lymphoma

    Eligibility Criteria - NCT02737046 *This information has been extracted from " www.clinicaltrials.gov"

  • AMC-095 - Ramos, Juan Carlos

  • Investigator:
    Juan Carlos Ramos
    RCname Email

    Coordinator:

    IRB: 20160656

    SDG: Leukemia, Lymphoma, and Myeloma
    Disease Site(s):

    Anus,Lip, Oral Cavity and Pharynx,Lung,Other Hematopoietic

    Sponsor: AMC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I Study of Ipilimumab and Nivolumab in Advanced HIV Associated Solid Tumors with an Expansion Cohort in HIV Associated Solid Tumors

    Eligibility Criteria - NCT02408861 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210989 - Schatz Jonathan

  • Investigator:
    Jonathan Schatz
    RCname Email

    Coordinator:

    IRB: 20210989

    SDG: Lymphoma
    Disease Site(s):

    Non-Hodgkin Lymphoma

    Sponsor: Memorial Sloan-Kettering Cancer Center

    Enrolling Sites:

    Sylvester

    Title:

    Phase I Multicenter Study of Ruxolitinib and Duvelisib in Relapsed or Refractory T- or NK-Cell Lymphomas

    Eligibility Criteria - NCT05010005 *This information has been extracted from " www.clinicaltrials.gov"

  • 20190836 - Wang Trent

  • Investigator:
    Trent Wang
    RCname Email

    Coordinator:
    RCemailImg Kirenia Correa
    RCphone +1 (305) 243-9590 x69590

    IRB: 20190836

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma,Leukemia, Other,Leukemia, not otherwise specified,Multiple Myeloma,Myeloid and Monocytic Leukemia,Non-Hodgkin Lymphoma,Other Hematopoietic

    Sponsor: EQUILLIUM INC

    Enrolling Sites:

    Sylvester

    Title:

    A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease

    Eligibility Criteria - NCT03763318 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201042 - Wang Trent

  • Investigator:
    Trent Wang
    RCname Email

    Coordinator:

    IRB: 20201042

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma,Leukemia, Other,Leukemia, not otherwise specified,Monocytic Leukemia,Multiple Myeloma,Mycosis Fungoides,Myeloid and Monocytic Leukemia,Non-Hodgkin Lymphoma,Other Hematopoietic

    Sponsor: AlloVir Inc

    Enrolling Sites:

    Sylvester

    Title:

    Phase 3 Multicenter, Double-Blind, Placebo-Controlled Trial of Viralym-M (ALVR105) for the Treatment of Patients With Virus-Associated Hemorrhagic Cystitis After Allogeneic Hematopoietic Cell Transplant (HCT)

    Eligibility Criteria - NCT04390113 *This information has been extracted from " www.clinicaltrials.gov"

  • 20201291 - Wang Trent

  • Investigator:
    Trent Wang
    RCname Email

    Coordinator:

    IRB: 20201291

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma,Leukemia, Other,Leukemia, not otherwise specified,Lymphoid Leukemia,Monocytic Leukemia,Multiple Myeloma,Mycosis Fungoides,Myeloid and Monocytic Leukemia,Non-Hodgkin Lymphoma,Other Hematopoietic

    Sponsor: AbGenomics International, Inc.

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I Study of Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease (Sr-aGVHD)

    Eligibility Criteria - NCT03327857 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210378 - Wang Trent

  • Investigator:
    Trent Wang
    RCname Email

    Coordinator:

    IRB: 20210378

    SDG: Lymphoma
    Disease Site(s):

    Hodgkin Lymphoma,Leukemia, Other,Leukemia, not otherwise specified,Lymphoid Leukemia,Monocytic Leukemia,Multiple Myeloma,Mycosis Fungoides,Myeloid and Monocytic Leukemia,Non-Hodgkin Lymphoma,Other Hematopoietic

    Sponsor: SYNDAX

    Enrolling Sites:

    Sylvester

    Title:

    AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy

    Eligibility Criteria - NCT04710576 *This information has been extracted from " www.clinicaltrials.gov"

  • S17-00978 - Watts, Justin

  • Investigator:
    Justin Watts
    RCname Email

    Coordinator:
    RCemailImg Rafael Perez
    RCphone +1 (786) 4245769

    IRB: 20180143

    SDG: Leukemia/heme
    Disease Site(s):

    Leukemia, Other

    Sponsor: NYULMC

    Enrolling Sites:

    Sylvester

    Title:

    S17-00978:A Phase Ib/IIa Study Evaluating the Safety and Tolerability ofVitamin C in Patients with Intermediate or high Risk Myelodysplastic Syndrome with TET2 Mutations

    Eligibility Criteria - NCT03433781 *This information has been extracted from " www.clinicaltrials.gov"